283173-82-0

Usage

Uses

Used in Pharmaceutical Research:
3-(4-Fluorophenoxy)phenylboronic acid is used as a key intermediate in the synthesis of new pharmaceutical compounds for [application reason]. Its boronic acid functionality allows for the creation of a diverse range of organic molecules with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 3-(4-Fluorophenoxy)phenylboronic acid is used as a reagent for [application reason], facilitating Suzuki-Miyaura cross-couplings and C-H activations to form complex organic structures.
Used in Agrochemical Industry:
3-(4-Fluorophenoxy)phenylboronic acid is employed as a precursor in the development of agrochemicals for [application reason], such as new pesticides or herbicides, leveraging its reactivity to create molecules with desired biological activities.
Used in the Development of Novel Chemical Entities:
3-(4-Fluorophenoxy)phenylboronic acid is used as a building block for the creation of novel chemical entities with potential applications in various industries, including pharmaceuticals and agrochemicals, for [application reason], such as enhancing the properties of existing compounds or introducing new functionalities.

Upstream product

• 150-46-9 triethyl borate 
• 50904-38-6 1-bromo-3-(4-fluorophenoxy)benzene 

Relevant academic research and scientific papers

Structure-guided discovery of a selective mcl-1 inhibitor with cellular activity

Myeloid cell leukemia 1 (Mcl-1), an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation when observed in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy, has emerged as an attractive target for cancer therapy. Here, we report the discovery of selective small molecule inhibitors of Mcl-1 that inhibit cellular activity. Fragment screening identified thienopyrimidine amino acids as promising but nonselective hits that were optimized using nuclear magnetic resonance and X-ray-derived structural information. The introduction of hindered rotation along a biaryl axis has conferred high selectivity to the compounds, and cellular activity was brought on scale by offsetting the negative charge of the anchoring carboxylate group. The obtained compounds described here exhibit nanomolar binding affinity and mechanism-based cellular efficacy, caspase induction, and growth inhibition. These early research efforts illustrate drug discovery optimization from thienopyrimidine hits to a lead compound, the chemical series leading to the identification of our more advanced compounds S63845 and S64315.